论文部分内容阅读
为探讨可溶性肿瘤坏死因子受体(sTNFR)与膀胱肿瘤生物学行为的关系,测定了26例膀胱移行细胞癌患者和20例正常对照者血清中(sTNFR)水平。发现膀胱癌患者血清sTNFR显著高于对照组(P<0.001),并随临床分期的增加而升高,术后两周时显著下降(P<0.01)。结果表明sTNFR抑制了血中肿瘤坏死因子的生物学活性而降低了机体的免疫功能,并可作为评估病情严重程度和预后的指标。
In order to investigate the relationship between soluble tumor necrosis factor receptor (sTNFR) and the biological behavior of bladder tumor, serum levels of sTNFR were measured in 26 patients with transitional cell carcinoma of the bladder and 20 normal controls. The serum level of sTNFR in bladder cancer patients was significantly higher than that in control group (P <0.001). The serum level of sTNFR increased with the increase of clinical stage and decreased significantly (P <0.01) two weeks after operation. The results show that sTNFR inhibits the biological activity of blood tumor necrosis factor and reduce the body’s immune function, and can be used as an assessment of the severity of the disease and prognosis indicators.